ldn
Start-Low-Go-Slow Protocols for MCAS, ME/CFS, and Autoimmune Disease Yoon Hang “John” Kim, MD, MPH, FAAMA Board-Certified Preventive Medicine | Integrative & Functional Medicine | LDN Research Trust Presenter The short version If you’ve been told LDN will make you better but every dose so far has
LDN Primer
Dr. Kim's LDN Primer Book which covers basics of LDN is now available in Amazon - https://www.amazon.com/dp/B0GZ9R4667/ref=sr_1_1?crid=Y99J3Z8DLKY2&dib=eyJ2IjoiMSJ9.Kq_wzqE15_OGnVOgkdQHbQdwZK32CtfPr6H9aL8NtC2JdRuLQJkskth03cPcjIrlnpNzzTw6NqVAdjbFJvOflQ.owU6k5lJ4jkFwPod1eq9pIC126Fde8sml1nlDi_ameE&dib_tag=se&keywords=Low+Dose+Naltrexone+%28LDN%29+Primer%3A+
hormone
CLINICAL EDUCATION SERIES Low-Dose Naltrexone and Hormonal Health: What the Evidence Actually Shows Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician www.directintegrativecare.com ABSTRACT Background: Low-dose naltrexone (LDN), administered at 1.5–4.5 mg nightly, is increasingly used off-
CIRS
By Yoon Hang Kim, MD, MPH | Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician Chronic illness patients — especially those navigating mold illness, Lyme disease, autoimmune conditions, or post-infectious syndromes — frequently encounter two acronyms that are both confusing and critically important: CIRS and MCAS. These conditions share a
Integrative Oncology
Cholangiocarcinoma (CCA) is an aggressive malignancy arising from the epithelial lining of the biliary tree. The disease is traditionally divided by anatomic origin into three subtypes: intrahepatic (iCCA, arising from small bile ducts within the liver), perihilar (pCCA, at the hepatic duct confluence), and distal (dCCA, within the extrahepatic bile
ldn
1. LDN is a Tool — Not a Cure-All LDN can be highly beneficial, especially for immune modulation, but it is not sufficient as a standalone therapy in most complex chronic illnesses. It should be viewed as a cornerstone, not the entire structure. 2. Individual Variability is the Rule Patient
LDN CKD Kidney Failure
Yoon Hang Kim, MD, MPH · www.directintegrativecare.com Low-dose naltrexone (LDN), typically dosed between 0.5 and 4.5 mg at bedtime, has become a widely used off-label therapy for autoimmune disease, chronic pain, and complex chronic illness. One of the questions I am asked most often in
ldn
Low-Dose Naltrexone (LDN): A Functional Medicine Approach to Autoimmunity, Lyme Disease, Long COVID, and Chronic Illness
ldn
Yoon Hang Kim, MD, MPH Board-Certified in Preventive Medicine | Integrative & Function Medicine Physician • www.directintegrativecare.com 0:00 /1:07 1× Introduction One of the most common questions I encounter in my LDN practice—and in the LDN Support Group community of over 9,000 members—is this:
ldn
1. Core Mechanism of LDN * Low Dose Naltrexone (LDN) temporarily blocks opioid receptors * This creates a transient drop in endorphins * The body typically responds by: * Increasing endogenous endorphin production * Leading to a rebound effect 2. Endorphin Deficiency Phenomenon * Not all patients compensate effectively * Some develop functional endorphin deficiency Clinical Presentation
ldn
Here’s the corrected and cleaned version with the name edited to Dr. Yoon Hang Kim: Hi, this is Dr. Yoon Hang Kim. I’m an expert in integrative and functional medicine, and I’m trying to figure out the best time to go live on Saturdays. I’m thinking
methylene blue
Yoon Hang Kim MD Skool Live Learning Summary — April 3, 2026 LDN, Methylene Blue & Integrative Fatigue Management: Key Clinical & Practical Insights Yoon Hang Kim, MD, MPH | Board-Certified: Preventive Medicine & Integrative/Holistic Medicine Osher Fellow University of Arizona Integrative Medicine Fellowship Graduate · IFM Scholarship Recipient· LDN Expert